Heartflow (NASDAQ:HTFL) Sets New 12-Month High on Analyst Upgrade

Heartflow, Inc. (NASDAQ:HTFL) shares hit a new 52-week high during mid-day trading on Saturday after JPMorgan Chase & Co. raised their price target on the stock from $35.00 to $45.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Heartflow traded as high as $43.00 and last traded at $42.08, with a volume of 9908709 shares traded. The stock had previously closed at $31.01.

A number of other analysts have also commented on HTFL. William Blair started coverage on Heartflow in a research note on Monday, May 4th. They set an “outperform” rating on the stock. Morgan Stanley raised their price objective on shares of Heartflow from $35.00 to $40.00 and gave the company an “equal weight” rating in a report on Friday. Freedom Capital upgraded shares of Heartflow to a “strong-buy” rating in a research report on Tuesday, June 30th. Benchmark reissued a “buy” rating on shares of Heartflow in a report on Friday. Finally, Wells Fargo & Company upped their price target on shares of Heartflow from $37.00 to $39.00 and gave the company an “overweight” rating in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Heartflow presently has an average rating of “Moderate Buy” and an average target price of $43.43.

Insider Buying and Selling

In other Heartflow news, CEO John C.M. Farquhar sold 22,562 shares of Heartflow stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $28.31, for a total value of $638,730.22. Following the completion of the sale, the chief executive officer directly owned 436,280 shares in the company, valued at approximately $12,351,086.80. The trade was a 4.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 106,586 shares of company stock worth $3,269,343 over the last ninety days. Company insiders own 7.70% of the company’s stock.

Key Stories Impacting Heartflow

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Heartflow reported second-quarter revenue of $64.1 million, up 47.7% year over year, while its adjusted loss of $0.07 per share beat the consensus estimate of a $0.22 loss. The results also showed improving profitability, with adjusted EBITDA losses narrowing to $6.7 million from $10.1 million a year earlier. Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
• Positive Sentiment: Management raised full-year 2026 revenue guidance to $246 million-$250 million from $228 million-$232 million, above the roughly $230 million analyst consensus, and projected non-GAAP gross margin of about 82%. HeartFlow Shares Soar Following Strong Q2 Results and Upgraded Guidance
• Positive Sentiment: Growth was supported by stronger U.S. FFRCT volume and increasing adoption of the Plaque product, suggesting Heartflow’s AI-based coronary disease platform is broadening beyond its core business.
• Positive Sentiment: Analysts raised their targets following the report: JPMorgan increased its target to $45 and Stifel raised its target to $45, with both firms maintaining bullish ratings. Wells Fargo also raised its target to $39 and retained an “overweight” rating. Analyst Price Target Updates
• Neutral Sentiment: The strong move pushed the stock near its 52-week high, potentially increasing volatility and making valuation a greater consideration for investors despite improving operating trends.
• Negative Sentiment: Insiders have reported repeated open-market sales, including a 22,562-share sale by CEO John C.M. Farquhar. The transaction was made under a pre-arranged Rule 10b5-1 plan, which reduces its significance as a discretionary bearish signal, but continued insider selling may still weigh on sentiment. Heartflow CEO Sells Shares

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in HTFL. Caitong International Asset Management Co. Ltd purchased a new position in Heartflow during the 4th quarter worth $27,000. Russell Investments Group Ltd. purchased a new stake in shares of Heartflow in the fourth quarter valued at about $45,000. Essential Partners LLC bought a new position in shares of Heartflow during the first quarter valued at about $57,000. Legal & General Group Plc purchased a new position in Heartflow during the third quarter worth about $59,000. Finally, Strs Ohio purchased a new position in Heartflow during the fourth quarter worth about $99,000.

Heartflow Stock Performance

The firm has a market capitalization of $3.63 billion and a P/E ratio of -22.99. The stock’s 50-day simple moving average is $29.08 and its 200-day simple moving average is $27.77.

Heartflow (NASDAQ:HTFL) last posted its earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.15. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.50%. The firm had revenue of $64.08 million for the quarter. Heartflow’s quarterly revenue was up 47.7% on a year-over-year basis. On average, equities research analysts expect that Heartflow, Inc. will post -0.82 EPS for the current year.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.